ClinicalTrials.gg
RecruitingNCT06483698EarlyLC-RWUpdated Aug 29, 2025

Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery

An observational study in Lung Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
20,000
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 10 open to participants now, 11 under way, none of them phase 3. Lung Neoplasms · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Started
2024
with 1 other
Observational
6 of 19
4 open now
Primary completion
2026-03
later than 3 of 10 live
Registered
12th of 19
by date

Among the 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is one of 2 that started in 2024, is one of 6 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 12th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

10 of the 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of early-stage lung cancer patients who have received surgery using the real-world data. The main questions it aims to answer are:

  • What is the best surgical strategy for patients with early-stage lung cancer?
  • What are the risk factors for early-stage lung cancer? Participants will receive surgery and the study will analyze the real-world data.
Read the detailed description

This observational study aims to comprehensively evaluate the effectiveness and long-term clinical outcomes of surgical interventions in early-stage lung cancer patients, utilizing real-world data.

Central to this investigation are two key questions:

  • What is the optimal surgical approach for managing early-stage lung cancer?
  • What are the primary risk factors associated with the development of early-stage lung cancer? Participants will undergo surgical procedures, and through rigorous analysis of real-world data, this study endeavors to provide nuanced insights into these fundamental queries, fostering advancements in clinical decision-making and patient management strategies.
03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with lung cancer who have received surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged between 18 and 85;
  2. Did not receive therapy before surgery;
  3. No history of radiation therapy;
  4. (ECOG) score is 0-1;
  5. Have complete information including imaging data;
  6. All patients underwent relevant preoperative examinations;
  7. Stage I lung cancer (International Association for the Study of Lung Cancer/The Union for International Cancer Control staging eighth edition);

Exclusion criteria

Exclusion Criteria:

  1. Have previously received chemotherapy, radiotherapy and other anti-tumor therapy;
  2. Data loss and error in medical records due to human/objective reasons.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
20,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Sublobar resection group

    Patients in this group have received Sublobar resection.

    Other: Sublobar resection

  • Lobectomy group

    Patients in this group have received lobectomy.

    Other: Lobectomy

Interventions

  • OtherSublobar resection

    Sublobar resection is a series of surgical approaches for lung cancer.

  • OtherLobectomy

    Lobectomy is the surgical approach for lung cancer.

06

What researchers measure

Primary outcomes

  1. Disease-free survival(DFS)

    Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).

    Time frame: Defined as the time from the date of surgery until the date of first documented progression or death (by any cause in the absence of recurrence), whichever came first, assessed up to 10 years.

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from surgery time until death from any cause.

    Time frame: From date of diagnosis until the date of death from any cause, whichever came first, assessed up to 10 years.

  2. 5-year Overall Survival (overall survival) Rate

    The time from surgery time until death from any cause, estimated from a Kaplan Meier plot of OS at the time of the primary analysis.

    Time frame: From date of surgery until date of death due to any cause. Assessed at 5 years.

  3. Patterns of Relapse

    Relapse was defined as disease recurrence at any site.

    Time frame: Within 10 years after surgery

  4. Perioperative Complication rate

    Complications after the surgery

    Time frame: Within 6 months after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Mar 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Jul 3, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Dec 2034
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06483698
Responsible party
Sponsor
First posted
Jul 3, 2024
Start date
Mar 1, 2024
Primary completion
Mar 2026 (estimated)
Completion
Dec 2034 (estimated)
Last update
Aug 29, 2025

Study contacts

Shugeng Gao, MD
Contact
gaoshugeng@cicams.ac.cn
8610-87788177
Shugeng Gao, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion